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Abstract Now that the laboratory mouse genome is
sequenced and the annotation of its gene content is
improving, the next major challenge is the annotation of
the phenotypic associations of mouse genes. This requires
the development of systematic phenotyping pipelines that
use standardized phenotyping procedures which allow
comparison across laboratories. It also requires the devel-
opment of a sophisticated informatics infrastructure for the
description and interchange of phenotype data. Here we
focus on the current state of the art in the description of
data produced by systematic phenotyping approaches using
ontologies, in particular, the EQ (Entity-Quality) approach,
and what developments are required to facilitate the linking
of phenotypic descriptions of mutant mice to human
diseases.
The laboratory mouse is a pivotal organism in under-
standing mammalian biology and gaining insight into
human diseases. Now that the mouse genome sequence is
available and annotation of genes and regulatory sequences
within it is improving rapidly, attention is shifting to how
genome information can be used to better understand
mammalian biology (Brown et al. 2006). Broadly, this
knowledge can be applied in two ways: (1) to gaining a
systems-level understanding of mouse biology leading to
an understanding of the effects of mutations and other
interventions on a variety of pathways giving rise to mutant
phenotypes, and (2) to the direct identiﬁcation of mouse
mutants with features that map directly onto human disease
phenotypes or aspects thereof. These new mouse strains
can then serve as disease models to improve our under-
standing of human pathobiology and support the develop-
ment of new approaches to therapy.
Both of these grand projects, which overlap to a con-
siderable extent, demand the systematic acquisition of
extensive phenotype data on mouse strains. For the sys-
tems-level approach, this is needed to relate phenotypes
that may have a common cause but different ultimate
manifestations at the level of the organism; for the more
directed approach it is important to identify as many con-
tributory phenodeviant components of the overall pheno-
type (endophenotypes) as possible to ensure that the
phenotype of a given strain can be accurately linked to its
cognate human disorder.
Mirroring the high-throughput vision of biology pio-
neered by the genome projects, mouse genetics is moving
into an era of large-scale data-gathering on phenotypes
based on the ability to carry out large-scale genome
manipulation, sequencing, and phenotyping. The system-
atic collection of mouse phenotype data started with the
Mouse Phenome Project (Bogue and Grubb 2004), initiated
in 1999, which collects data on a large panel of inbred
lines. A database, the Mouse Phenome Database (MPD)
(Bogue et al. 2007; Grubb et al. 2004), is an integral part of
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variety of centres both to allow for data dissemination and
to provide tools for the comparative analysis of strains.
The Mouse Phenome Project collects data on many
mouse lines in a single laboratory. For example, data from
a large-scale aging project carried out at The Jackson
Laboratory (http://agingmice.jax.org/index.html) will soon
deposit age-related phenotype data for 32 inbred strains of
mice into the MPD. This approach to phenotyping ensures
reproducibility of individual types of measurement but has
problems of scalability—how many lines is an individual
laboratory able to analyse?—and confounding factors such
as environment, assay, or equipment variation mean that
any meta- or coanalysis of different measurements is not
possible across laboratories. The problem of scalability is
addressed by an alternative structure, pioneered by the
EUMORPHIA project in Europe (Brown et al. 2006), in
which more than one centre carries out all phenotyping
tests, and efforts are made to make all of those tests as
reproducible as possible between centres. EUMORPHIA’s
aim was to produce a panel of reproducible phenotyping
tests that could be used in such a project in the form of
SOPs (standard operating procedures) and to test these on a
number of inbred lines. The project resulted in the
EMPReSS collection of SOPs (Brown et al. 2005). Com-
parability between tests is also addressed by this approach,
although it remains to be established to what extent com-
parison of lines between laboratories can be achieved.
A natural complement to the Mouse Phenome Project
and EUMORPHIA is the collection of phenotype data on
mutant mouse lines, rather than inbred background strains,
using the same concept of standardized phenotyping pro-
cedures. This is currently the aim of the EUMODIC project
(http://www.eumodic.org/), a follow-on from EUMOR-
PHIA. Here, four large mouse clinics—MRC Harwell and
the Sanger Institute in the UK, the Helmholtz Zentrum in
Germany, and the Institut Clinique de la Souris in France—
carry out phenotyping using standard pipelines, making use
primarily of gene knockout lines from the EUCOMM
project (Friedel et al. 2007), part of the International
Knockout Mouse Consortium (Gondo 2008). The beneﬁt of
using EUCOMM lines in EUMODIC is that because all
mice are derived from the same embryonic stem (ES) cell
line, there is minimal interindividual genetic variation,
allowing for more robust identiﬁcation of phenotype-gene
relationships.
Both EUMORPHIA and EUMODIC are distributed
projects with data being generated at different international
centres. The only sensible approach to such data-gathering
exercises, as illustrated by the Mouse Phenome Project, is
to set up a central data repository. The SOP collection from
EUMORPHIA was collected in the EMPReSS database
(Green et al. 2005)( http://empress.har.mrc.ac.uk/), which
contains all the EUMORPHIA SOPs in a structured form.
Data from EUMORPHIA, and subsequently EUMODIC,
have been collected in the EuroPhenome database (Mallon
et al. 2008)( http://www.europhenome.org).
Of course, these high-throughput approaches are of value
only if complemented by the gathering of more detailed
information on lines of particular relevance to disease.
Pathological examination, which is not part of high-
throughput phenotyping pipelines because of its cost and
relatively time-consuming nature, is an important part of
this because without this the lines that are identiﬁed are less
likely to be adopted by the relevant disease communities.
Inspection of the data generated by the EMPReSS SOPs
and held in EuroPhenome immediately reveals that phe-
notyping data are much more diverse than the kinds of data
bioinformaticians are used to handling, e.g., sequence data.
Many of the observations that need to be held in a phe-
notyping database are either descriptive or involve infer-
ences from raw data. Any type of data that to a signiﬁcant
extent comprises free text causes immediate problems for
data analysis because different experimenters may use the
same term for different things or different terms for the
same thing. This semantic problem has led to the increas-
ingly broad uptake in biology of ontologies, starting with
the gene ontology (Ashburner et al. 2000). Ontologies are
formal structures that consist of two elements: standard
terms that can be used to describe a domain of knowledge
and relationships linking those terms. Classically, in bio-
ontologies these relationships are of the form ‘‘is_a,’’ e.g.,
an eye ‘‘is_a’’ sensory organ, or ‘‘part_of,’’ e.g., an eye is
‘‘part_of’’ the head. The beneﬁt of including such rela-
tionships is that it is possible computationally to relate data
on the eye, in this case, to other data relating to the head or
to other sensory organs.
The ﬁrst use of ontologies to describe mouse phenotypes
was the Mammalian Phenotype Ontology (MP), which
continues to be developed at The Jackson Laboratory
(Smith et al. 2005). This is used in the Mouse Genome
Database (MGD) (Blake et al. 2009) to annotate the
abnormal phenotypes of mouse strains and lines. The MP
currently contains over 9000 terms and is an immensely
powerful tool for mouse line annotation. However, it is not
suitable for the detailed description of data generated by
high-throughput phenotyping projects for a number of
reasons. First, all phenotypes described by the MP are
abnormal, whereas much, perhaps most, of the data gen-
erated by high-throughput phenotyping is normal. Indeed,
within EuroPhenome no judgment of normal or abnormal
is made on raw data held in the database; any such anno-
tations are made by inference, which is increasingly done
by automatic reasoning. Second, MP does not allow the
description of quantitative values obtained in phenotyping
experiments.
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because its terms contain combinations of terms that exist in
other, more fundamental ontologies such as the mouse
anatomy ontology and the Gene Ontology. An alternative to
the pre-composed structure of the MP ontology is the ‘‘post-
composed’’ structure implemented in the EQ approach
(Gkoutos et al. 2004, 2005). The EQ approach is based on
the Phenotype And Trait Ontology (PATO), an ontology of
phenotypic qualities intended for use in a number of
applications, primarily phenotype annotation. According to
this approach, phenotypic descriptions can be abstracted
into two parts: an entity that is affected (the thing for which
measurements are made), be it an enzyme, an anatomical
structure, or a biological process, and the quality of that
entity, described either qualitatively or quantitatively. At a
bare minimum all phenotypes are described using a class
expression consisting of a quality class (from PATO) dif-
ferentiated by a bearer entity class (from some other open
biomedical ontologies, OBO ontology) using the inheres_in
relation (from the OBO Relation Ontology RO). One way of
expressing phenotype annotation using PATO is the so-
called pheno-syntax, which is adopted in EuroPhenome. In
its simplest form a pheno-syntax tuple can be E = MA:liver
Q = PATO:hyperplastic to describe a ‘‘hyperplastic liver’’
phenotype. (Formally, this description is compiled using the
IDs of terms from the ontologies rather than their names
because names are not necessarily ﬁxed, whereas IDs are
stable; we are using term names here for clarity.)
The pre- and post-composition approaches are com-
pletely compatible provided that equivalence relationships
to EQ descriptions are generated for pre-composed ontol-
ogy terms. The MP, for example, does have a term
describing ‘‘liver hyperplasia’’ (MP:0005141). If an
equivalence relationship mapping is provided, then these
two descriptions can be used interchangeably. In OBO 1.2
syntax, this could be represented as
[Term]
id: MP:0005141 ! liver hyperplasia
intersection_of: PATO:0000644 ! hyperplastic
intersection_of: inheres_in MA:0000358 ! liver
This is a very powerful aspect of EQ because it provides
the potential to link different ontologies at a basic level,
allowing for a common mapping of different phenotype
ontologies through logical deﬁnitions and ‘‘phenotype (EQ)
statements.’’ The liver hyperplasia example is a relatively
simple one which serves to illustrate how EQ statements
can be constructed. However, many disease terms are much
more complex and require a more detailed description. EQ
allows for complex phenotype descriptions such as disease
terms by allowing the creation of a phenotypic proﬁle
formed by several EQ statements. For example, for the
term ‘‘osteoporosis’’ a set of EQ statements would be
required to describe ‘‘increased bone resorption’’ and
‘‘decreased osteogenesis’’ that results_in ‘‘decreased bone
mass’’ and ‘‘increased bone fragility.’’
MP terms, which have been created largely by pheno-
typing scientists using community-agreed-on terminology,
can be standardised by using EQ-based logical deﬁnitions.
For example, the MP term belly spot (MP:0000373), which
is a term widely used by the phenotyping community,
deﬁnes the pigmentation phenotype characterised by ‘‘the
appearance of a round area of white fur on the belly’’ (this
is the MP deﬁnition). The belly spot term could be logically
deﬁned based on the EQ approach as ‘‘white’’
(PATO:0000323) ‘‘spotted’’ (PATO:0000333) ‘‘coat hair’’
that is part_of ‘‘abdomen’’ (MA:0000029).
Such an EQ-based logical deﬁnition does not deﬁne a
phenotype as being intrinsically ‘‘abnormal’’ and can pro-
vide new relationships between the MP terms through the
use of predeﬁned entity and quality terms. For example, the
MP uses the labels ‘‘belly’’ and ‘‘abdomen’’ to deﬁne the
same concept, in line with community use. However, MA
deﬁnes the single concept (abdomen) which can be used to
link the MP terms containing both ‘‘belly’’ and ‘‘abdomen’’
at the EQ level.
These kinds of mappings are a new area of development
in the phenotype ontology ﬁeld and require some signiﬁ-
cant issues to be addressed. First, there is a need to
appropriately logically deﬁne the relevant pre-composed
ontologies. This is an issue of both manpower and expertise
as many of the terms in pre-composed ontologies have
specialist meanings that require specialist input into the
deﬁnition process to ensure that they are broken down
correctly. Second, the underlying ontological infrastructure
is still patchy. While anatomy and quality ontologies exist
for mouse phenotypes, there is currently no behaviour
ontology that can be used to deﬁne behaviour-related
phenotype terms. From the perspective of human disease
there is a need for an intermediate level between disease
terms and human ‘‘phenotypes’’ that can be linked to
mouse phenotypes (Schoﬁeld et al. 2008). This missing
layer may be ﬁlled by the new Human Phenotype Ontology
(HPO) (Robinson et al. 2008), which currently describes
phenotypes that are components of diseases in the OMIM
database, but this is still in the early stage of development
and the provision of logical deﬁnitions for HPO and
mapping to the mouse will be required.
A long-term aim of building these links is to facilitate
the construction of reasoner software that can link pheno-
types in the mouse automatically to human diseases and
phenotypes in other organisms. EQ can already be used in
the automatic annotation of phenotypes in mutant lines
(Beck et al. 2009). Annotation of lines in EuroPhenome,
which is currently the only mammalian database to use the
EQ formalism, to a considerable extent is automated and
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EMPReSS SOP database and the data on baseline strains
and mutant lines in EuroPhenome. EMPReSS SOPs deﬁne
the traits (or parameters) to be measured, e.g., ‘‘body
weight.’’ The raw body weight data for the mutant line and
the corresponding background strain are stored in Euro-
Phenome. If the mutant line’s body weight is found to be
signiﬁcantly increased or decreased after the application of
a statistical test, then the relevant EQ annotation is applied
to the mutant strain, e.g., ‘‘adult mouse’’ (MA:0002405)
‘‘increased weight’’ (PATO:0000582). For more detail on
the automated annotation in EuroPhenome see Beck et al.
(2009).
An important area for future development in phenotype
bioinformatics will be the linking of disparate data sets to
form a phenotype semantic web (Gkoutos 2006). As with all
semantic web applications, this will depend on standard
formats for semantic representation (ontologies) and data
transfer(XMLandRDF).Fromtheperspectiveofontologies
it will be essential to ensure that all the necessary deﬁnitions
and cross-mappings are established and maintained. At the
level of data transfer, data standards for describing pheno-
type data still need to be established, although formats such
as the XML used to transfer data within EUMODIC repre-
sent a ﬁrst step in this direction. Encouragingly, there is
broad agreement in the mouse phenotype database commu-
nity (Mouse Phenotype Database Integration Consortium
2007), and more broadly in the mouse functional genomics
community (Hancock et al. 2008), that these developments
are needed and the Interphenome Consortium (Mouse Phe-
notype Database Integration Consortium 2007) has met
twice a year since 2007 to work toward these goals. It is
possible to link many databases together at the naı ¨ve level
using tools such as BioMart (Smedley et al. 2005), and more
complex integration of data using a variety of mechanisms
has recently been demonstrated by the European CASIMIR
consortium (Smedley et al. 2008). However, a fully func-
tional integration of mouse phenotype data ultimately will
require a more sophisticated, ﬂexible infrastructure, mostly
likely basedon webservices(Stein 2002,2008).Asurveyof
mousefunctionalgenomicsdatabases(Hancocketal.2008),
also by CASIMIR, suggested that these more sophisticated
technologies are being taken up with increasing enthusiasm
by database providers, raising the prospect that this cyber-
infrastructure will come into existence over the next few
years.
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